N. meningitidis serogroup B strain is the most prevalent form of invasive meningococcal disease in Canada. Although this infection is relatively rare, no other bacterial agent may kill as swiftly after bloodstream invasion as the meningococcus. With the availability of vaccines to protect against the different serogroups, it is important for clinicians to educate patients on the potential risks of meningococcal infection and the benefits of immunization. This program will review the clinical consequences of meningococcal type B infection, the different vaccine options and how it can be integrated into practice.
This program has received an unrestricted educational grant or in-kind support from GSK.